Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina
Conditions
Interventions
IMB-1018972
Placebo oral tablet
Locations
1
United States
Imbria Investigational Site
Boston, Massachusetts, United States
Start Date
May 1, 2020
Primary Completion Date
February 1, 2025
Completion Date
April 1, 2025
Last Updated
November 10, 2025
NCT06571370
NCT05174572
NCT04915157
NCT03438500
NCT03350737
NCT02499250
Lead Sponsor
Imbria Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions